Halozyme Therapeutic News (AMEX:HTI)
| Latest Halozyme Therapeutic News Headlines | | Date | Time | Source | | | 05/07/2007 | 8:00AM | PRNUS | Halozyme Therapeutics to Hold Business Update Conference Call on May 11
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will release financial results for the three months ended March 31, 2007 after market close on Thursday, May 10, 2007.
Jonathan... More...>> |
| 05/02/2007 | 8:00AM | PRNUS | Halozyme Therapeutics to Present at May Investment Conferences
SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present at the following investment conferences during... More...>> |
| 05/02/2007 | 8:00AM | PRNUS | Halozyme Therapeutics to Present at May Investment Conferences
SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present at the following investment conferences during... More...>> |
| 04/30/2007 | 8:00AM | PRNUS | Halozyme Therapeutics Announces Nasdaq Global Market Listing Approval
Halozyme Shares Expected to Commence Trading on May 10, Under the Ticker Symbol HALO
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Nasdaq has approved the Company's application... More...>> |
| 04/27/2007 | 9:00AM | PRNUS | Baxter Introduces HYLENEX for Use in Ophthalmic Surgery
SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced availability of HYLENEX recombinant (hyaluronidase human injection) for the ophthalmology market for use in enhancing the absorption and dispersion of other injected drugs. HYLENEX is the first and only human recombinant hyaluronidase... More...>> |
| 04/24/2007 | 8:00AM | PRNUS | Halozyme Therapeutics Announces $32.1 Million Private Financing
SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it has entered into a definitive stock purchase agreement with New River Management V, LP ("New River") for a $32.1 million... More...>> |
| 03/13/2007 | 6:00PM | PRNUS | Halozyme Therapeutics Adopts SEC Rule 10b5-1 Policy
SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI) announced today that its Board of Directors has adopted a policy that provides for the use of pre-arranged trading plans by persons subject to the company's insider trading policy. All such pre-arranged trading plans must (i) comply... More...>> |
| 03/08/2007 | 8:00AM | PRNUS | Halozyme Therapeutics Reports Fourth Quarter and Year End 2006 Financial Results
- Conference Call and Webcast Today at 8:00 a.m. PST -
SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today reported financial results for the three months and year ended December 31, 2006.
"We... More...>> |
| 03/07/2007 | 8:00AM | PRNUS | Halozyme Therapeutics to Present at the Cowen & Company 27th Annual Health Care Conference
SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the Cowen & Company 27th Annual Health Care Conference to be held at the Boston Marriott Copley Place in Boston... More...>> |
| 03/06/2007 | 8:00AM | PRNUS | Halozyme Therapeutics to Hold 2006 Fourth Quarter and Year End Conference Call on March 8
SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will release financial results for the three and twelve months ended December 31, 2006 prior to market open on Thursday, March... More...>> |
| 02/14/2007 | 4:31PM | PRNUS | Halozyme Therapeutics and Baxter Present Promising Results for the Use of HYLENEX From the Infuse-Morphine Study
-- HYLENEX Accelerates the Time to Peak Blood Concentration for Subcutaneous Morphine with Acceptable Tolerability --
SAN DIEGO and DEERFIELD, Ill, Feb. 14 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI) and Baxter Healthcare today announced the presentation of results of a Phase IIIB clinical trial... More...>> |
| 02/14/2007 | 8:00AM | PRNUS | Halozyme and Baxter Expand Global HYLENEX Collaboration
Total Collaboration Valued at Up to $65 Million, Including a $20 Million Equity Investment in Halozyme
SAN DIEGO and DEERFIELD, Ill., Feb. 14 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI) and Baxter Healthcare Corporation announced today they have expanded their existing HYLENEX recombinant (hyaluronidase... More...>> |
| 02/13/2007 | 8:00AM | PRNUS | Halozyme therapeutics to Present at the Roth Capital Partners 19th Annual OC Conference
SAN DIEGO, Feb. 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the Roth Capital Partners 19th Annual OC Conference to be held at The Ritz Carlton in Laguna Niguel, Calif... More...>> |
| 01/22/2007 | 8:00AM | PRNUS | Halozyme Therapeutics Releases Results of Enhanze Technology Clinical Trial to Improve the Subcutaneous Absorption of a Large Pr
- Use of rHuPH20 Increases the Bioavailability of Subcutaneously Injected Biologic Therapeutic Agent -
SAN DIEGO, Jan. 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced the results of a clinical trial... More...>> |
| 01/03/2007 | 8:00AM | PRNUS | Halozyme Therapeutics to Present at the JPMorgan 25th Annual Healthcare Conference
SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the JPMorgan 25th Annual Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco... More...>> |
| 12/05/2006 | 5:48PM | PRNUS | Halozyme and Roche Enter Agreement for the Application of Enhanze, A Novel Technology to Improve Drug Delivery
BASEL, Switzerland and SAN DIEGO, Dec. 5 /PRNewswire/ -- Halozyme Therapeutics, Inc. (AMEX:HTI) and Roche today announced they have entered into an agreement to apply Halozyme's proprietary Enhanze(TM) Technology to Roche's biological therapeutic compounds. Enhanze Technology is Halozyme's proprietary drug delivery... More...>> |
| 11/27/2006 | 8:00AM | PRNUS | Halozyme Therapeutics Completes Enrollment of Enhanze Technology Clinical Trial to Improve the Subcutaneous Absorption of a Larg
SAN DIEGO, Nov. 27 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced it has completed the enrollment of a clinical trial of Enhanze(R) Technology, Halozyme's enzyme-based drug delivery platform based... More...>> |
| 11/27/2006 | 8:00AM | PRNUS | Halozyme Therapeutics Completes Enrollment of Enhanze Technology Clinical Trial to Improve the Subcutaneous Absorption of a Larg
SAN DIEGO, Nov. 27 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced it has completed the enrollment of a clinical trial of Enhanze(R) Technology, Halozyme's enzyme-based drug delivery platform based... More...>> |
| 11/20/2006 | 8:00AM | PRNUS | Halozyme Therapeutics to Present at the Lazard Capital Markets Third Annual Life Sciences Conference
SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the Lazard Capital Markets Third Annual Life Sciences Conference to be held at the Palace Hotel in New York... More...>> |
| 11/20/2006 | 8:00AM | PRNUS | Halozyme Therapeutics to Present at the Lazard Capital Markets Third Annual Life Sciences Conference
SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the Lazard Capital Markets Third Annual Life Sciences Conference to be held at the Palace Hotel in New York... More...>> |
|
|
|